Hepatocellular carcinoma
Conditions
Interventions
Miriplatin-TACE group We used Miriplatin(Miripla, Dainippon-Sumitomo Pharmaceutical Co. Ltd., Osaka, Japan) mixed with LPD (iodized oil
Andre Guerget, Aulnay-sous-Bois, France). The Miriplatin-LPD suspension was prepared by mixing 70 mg of DDPH into 3-10 mL of LPD. The dosage of LPD and the anticancer drugs was adjusted depending
Nipponkayaku, Tokyo, Japan) mixed with contrast medium.
DDPH-TACE group We used DDPH(IA-call
Nipponkayaku, Tokyo, Japan) mixed with LPD (iodized oil
Andre Guerget, Aulnay-sous-Bois, France). The DDPH-LPD suspension was prepared by mixing 50 mg of DDPH into 3-10 mL of LPD. The dosage of LPD and the anticancer drugs was adjusted depending on the
Sponsors
Iwate Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Eligibility criteria 1) No indication for surgical resection or local ablation therapy such as RFA and PEI therapy; 2) No evidence of extra hepatic metastasis; 3) No tumor thrombus in the main trunk of portal vein. 4) No evidence of active heart or renal diseases meeting the contraindications for ADM and CDDP therapy, respectively; 5) Eastern Cooperative Oncology Group (ECOG) performance status (PS) [22] level 0-2; 6) Hypervascular tumors showing enhancement during angiography; 7) Bidimensionally measurable hepatic lesions; 8) No uncontrolled ascites or pleural effusion; 9) Total serum bilirubin (T-Bil) less than 3 mg/dL.
Exclusion criteria
Exclusion criteria: Exclusion criteria 1) Pregnancy woman 2) Patients who had allergic and severe disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary efficacy endpoint of the current study is the objective response rate. | — |
Countries
Japan
Outcome results
None listed